Study of Blood Levels of Rituximab and Ocrelizumab in Adults With Relapsing-Remitting Multiple Sclerosis

What this Trial Is About

This research investigates personalized treatment options using rituximab and ocrelizumab for patients with relapsing-remitting multiple sclerosis RRMS diagnosed within the last year. It is a substudy of the larger OVERLORD-MS trial, aiming to see if rituximab is as effective and safe as ocrelizumab in treatment-nave RRMS patients. The study focuses on how measuring drug levels in the blood might help tailor treatments to individual needs. Participants receive either rituximab or ocrelizumab according to the main studys protocol. Blood samples are taken at specific times before and after infusions to measure the serum concentrations of these drugs using advanced laboratory methods called liquid chromatography tandem mass spectrometry LC-MSMS. This helps researchers understand how the drugs behave in the body and relate these levels to treatment outcomes. During the study, participants will provide blood samples at scheduled visits up to 24 weeks, covering one treatment cycle with infusions every six months. Researchers will analyze these samples alongside clinical data to explore the relationship between drug levels, biochemical markers, and patient responses. This approach aims to improve treatment personalization and monitoring in RRMS.

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis